Safwan Jaradeh, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 3 carriers
- Office
- 1
- Since medical school
- 47 years
- Graduated 1979
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
6 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jaradeh’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C54540 · Current
Licensed to practise in California · since 2011 · expires 2027-02-28 · University of Damascus Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Clinical Neurophysiology
- American Board of Psychiatry and Neurology - Neurology
- American Board of Psychiatry and Neurology - Neuromuscular Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$40,527
Medicare paid this office $40,527 for 231 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 68 | $9,961 | $126 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 78 | $5,670 | $72 |
| Nerve test | 28 | $3,252 | $116 |
| Testing of autonomic (sympathetic) nervous system function | 71 | $2,708 | $38 |
| New patient visit (60+ min) | 17 | $2,703 | $159 |
See all 13 services
| Long return visit (40+ min) | 68 | $9,961 | $126 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 78 | $5,670 | $72 |
| Nerve test | 28 | $3,252 | $116 |
| Testing of autonomic (sympathetic) nervous system function | 71 | $2,708 | $38 |
| New patient visit (60+ min) | 17 | $2,703 | $159 |
| Muscle electrical test | 49 | $2,383 | $41 |
| Return visit (30+ min) | 14 | $2,228 | $124 |
| Return visit (30+ min) | 23 | $1,909 | $80 |
| Nerve test | 14 | $1,349 | $96 |
| Muscle electrical test | 36 | $896 | $17 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 52 | $854 | $15 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $423 | $28 |
| Muscle electrical test | 11 | $369 | $34 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
231 Original Medicare patients in 2024. Average age 71 · Under 65 17% · 85 and older 7% · Women 55% · Also on Medicaid 15% · Health risk score 1.64. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 68% · Depression 33% · Coronary heart disease 29% · Diabetes 24% · Atrial fibrillation 24% · Chronic kidney disease 22% · Cancer 19% · Heart failure 18% · Stroke 17% · COPD 11% · Dementia 8%.
The office billed $787,931, Medicare allowed $52,747 and paid $40,527; for 610 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 231 | 610 | 71 | 1.64 | $787,931 | $40,527 |
| 2023 | 196 | 490 | 73 | 1.52 | $730,766 | $36,573 |
| 2022 | 178 | 426 | 71 | 1.59 | $512,015 | $33,785 |
| 2021 | 187 | 496 | 70 | 1.56 | $497,988 | $39,554 |
| 2020 | 191 | 447 | 70 | 1.72 | $443,649 | $31,179 |
| 2019 | 231 | 603 | 69 | 1.73 | $619,672 | $41,045 |
| 2018 | 220 | 531 | 68 | 1.68 | $546,810 | $36,016 |
| 2017 | 200 | 527 | 69 | 1.72 | $458,238 | $36,386 |
| 2016 | 171 | 432 | 68 | 1.46 | $392,317 | $30,111 |
| 2015 | 208 | 534 | 68 | 1.83 | $330,100 | $39,882 |
| 2014 | 165 | 428 | 67 | 1.65 | $215,867 | $28,425 |
| 2013 | 226 | 601 | 67 | 1.63 | $201,585 | $44,090 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 63 | $9,108 | $121 |
| New patient visit (60+ min) | 29 | $4,622 | $159 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 47 | $3,499 | $74 |
| Nerve test | 30 | $3,441 | $115 |
| Muscle electrical test | 60 | $3,130 | $41 |
| Return visit (30+ min) | 19 | $2,258 | $87 |
| Testing of autonomic (sympathetic) nervous system function | 41 | $1,660 | $40 |
| Nerve test | 11 | $1,620 | $147 |
| Nerve test | 12 | $1,093 | $91 |
| Nerve test | 12 | $890 | $74 |
| Muscle electrical test | 32 | $684 | $16 |
2022: 9 services
| Long return visit (40+ min) | 68 | $9,912 | $117 |
| New patient visit (60+ min) | 25 | $3,918 | $157 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 38 | $3,039 | $80 |
| Nerve test | 23 | $2,819 | $123 |
| Return visit (30+ min) | 25 | $2,547 | $85 |
| Muscle electrical test | 41 | $1,874 | $43 |
| Testing of autonomic (sympathetic) nervous system function | 36 | $1,506 | $42 |
| Nerve test | 14 | $1,409 | $101 |
| Muscle electrical test | 36 | $900 | $17 |
2021: 10 services
| New patient visit (60+ min) | 45 | $8,388 | $186 |
| Long return visit (40+ min) | 55 | $8,350 | $127 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 49 | $3,351 | $68 |
| Return visit (30+ min) | 34 | $3,141 | $87 |
| Muscle electrical test | 49 | $2,674 | $43 |
| Nerve test | 17 | $2,170 | $128 |
| Nerve test | 18 | $1,848 | $103 |
| Testing of autonomic (sympathetic) nervous system function | 48 | $1,709 | $34 |
| Nerve test | 14 | $1,073 | $77 |
| Muscle electrical test | 38 | $803 | $16 |
2020: 10 services
| Return visit (30+ min) | 58 | $5,412 | $68 |
| New patient visit (60+ min) | 37 | $5,109 | $138 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 44 | $3,592 | $82 |
| Nerve test | 18 | $2,442 | $129 |
| Long return visit (40+ min) | 21 | $2,288 | $104 |
| Nerve test | 22 | $2,282 | $104 |
| Muscle electrical test | 36 | $1,684 | $41 |
| Testing of autonomic (sympathetic) nervous system function | 36 | $1,534 | $43 |
| Muscle electrical test | 36 | $989 | $18 |
| Short return visit (20+ min) | 18 | $907 | $48 |
2019: 11 services
| Return visit (30+ min) | 60 | $5,200 | $64 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 64 | $4,936 | $77 |
| New patient visit (60+ min) | 32 | $4,564 | $143 |
| Long return visit (40+ min) | 38 | $4,442 | $101 |
| Nerve test | 28 | $3,450 | $123 |
| Testing of autonomic (sympathetic) nervous system function | 62 | $2,389 | $38 |
| Muscle electrical test | 40 | $1,988 | $42 |
| Nerve test | 19 | $1,816 | $96 |
| Muscle electrical test | 54 | $1,450 | $17 |
| Nerve test | 12 | $897 | $75 |
| Muscle electrical test | 17 | $636 | $33 |
2018: 15 services
| Return visit (30+ min) | 53 | $4,138 | $67 |
| New patient visit (60+ min) | 26 | $3,477 | $134 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 38 | $2,877 | $76 |
| Long return visit (40+ min) | 23 | $2,020 | $88 |
| Nerve test | 16 | $1,589 | $99 |
| Muscle electrical test | 33 | $1,529 | $40 |
| Testing of autonomic (sympathetic) nervous system function | 37 | $1,501 | $38 |
| Return visit (30+ min) | 20 | $1,413 | $71 |
| Nerve test | 12 | $1,408 | $117 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 17 | $1,374 | $81 |
| Muscle electrical test | 26 | $644 | $17 |
| Muscle electrical test | 13 | $599 | $43 |
| Testing of autonomic (sympathetic) nervous system function | 14 | $585 | $42 |
| Muscle electrical test | 12 | $422 | $35 |
| Muscle electrical test | 14 | $383 | $16 |
2017: 12 services
| Return visit (30+ min) | 56 | $4,878 | $65 |
| New patient visit (60+ min) | 32 | $4,494 | $140 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 56 | $4,481 | $80 |
| Long return visit (40+ min) | 34 | $3,478 | $99 |
| Muscle electrical test | 11 | $2,958 | $141 |
| Testing of autonomic (sympathetic) nervous system function | 62 | $2,630 | $41 |
| Muscle electrical test | 42 | $2,178 | $41 |
| Nerve test | 15 | $1,833 | $122 |
| Nerve test | 15 | $1,487 | $99 |
| Nerve test | 17 | $1,264 | $74 |
| Muscle electrical test | 32 | $730 | $17 |
| Muscle electrical test | 15 | $486 | $32 |
2016: 11 services
| New patient visit (60+ min) | 36 | $5,101 | $142 |
| Return visit (30+ min) | 46 | $3,852 | $68 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 44 | $3,487 | $79 |
| Long return visit (40+ min) | 24 | $2,347 | $98 |
| Testing of autonomic (sympathetic) nervous system function | 51 | $2,132 | $42 |
| Muscle electrical test | 36 | $1,917 | $43 |
| Nerve test | 12 | $1,473 | $123 |
| Evaluation of heart function using tilt table | 14 | $1,188 | $85 |
| Nerve test | 12 | $1,104 | $92 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 14 | $577 | $41 |
| Muscle electrical test | 25 | $573 | $17 |
2015: 13 services
| Return visit (30+ min) | 62 | $6,031 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $4,935 | $93 |
| Long return visit (40+ min) | 33 | $3,578 | $99 |
| New patient visit (60+ min) | 23 | $3,280 | $143 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 37 | $2,809 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,693 | $121 |
| Evaluation of heart function using tilt table | 17 | $1,452 | $85 |
| Muscle electrical test | 29 | $1,433 | $42 |
| Testing of autonomic (sympathetic) nervous system function | 34 | $1,414 | $42 |
| Nerve test | 12 | $885 | $74 |
| Nerve test | 13 | $700 | $54 |
| Muscle electrical test | 30 | $672 | $17 |
| Muscle electrical test | 16 | $559 | $35 |
2014: 11 services
| Return visit (30+ min) | 57 | $5,330 | $68 |
| New patient visit (60+ min) | 29 | $3,992 | $138 |
| Evaluation of heart function using tilt table | 41 | $3,029 | $74 |
| Long return visit (40+ min) | 26 | $2,467 | $95 |
| Testing of autonomic (sympathetic) nervous system function | 39 | $1,586 | $41 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 39 | $1,534 | $39 |
| Nerve test | 14 | $1,257 | $90 |
| Nerve test | 16 | $1,142 | $71 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 12 | $956 | $80 |
| Muscle electrical test | 22 | $914 | $42 |
| Muscle electrical test | 26 | $516 | $17 |
2013: 14 services
| New patient visit (60+ min) | 54 | $7,745 | $143 |
| Long return visit (40+ min) | 52 | $5,150 | $90 |
| Return visit (30+ min) | 51 | $4,383 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,841 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,088 | $88 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 41 | $3,073 | $75 |
| Testing of autonomic (sympathetic) nervous system function | 53 | $2,222 | $42 |
| Evaluation of heart function using tilt table | 25 | $1,951 | $78 |
| Nerve test | 25 | $1,711 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $994 | $62 |
| Muscle electrical test | 25 | $968 | $33 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 20 | $799 | $40 |
| Nerve test | 13 | $705 | $54 |
| Muscle electrical test | 22 | $553 | $17 |
Drugs they prescribed that Part D paid
$275,931
Pharmacies billed $275,931 in 2024. Most of that is one immune-globulin drugs at about $4,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 403) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
361 generic and 42 brand-name prescriptions · $275,931 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gammagard Liquid | Immune globulin | 36 | $128,683 | $3,575 |
| Midodrine | None | 80 | $3,572 | $45 |
| Pyridostigmine | None | 57 | $1,926 | $34 |
| Droxidopa | None | 13 | $1,803 | $139 |
| Atomoxetine | None | 12 | $1,092 | $91 |
See all 8 drugs
| Gammagard Liquid | Immune globulin | 36 | $128,683 | $3,575 |
| Midodrine | None | 80 | $3,572 | $45 |
| Pyridostigmine | None | 57 | $1,926 | $34 |
| Droxidopa | None | 13 | $1,803 | $139 |
| Atomoxetine | None | 12 | $1,092 | $91 |
| Fludrocortisone Acetate | None | 26 | $579 | $22 |
| Baclofen | None | 25 | $161 | $6 |
| Gabapentin | None | 12 | $52 | $4 |
Year by year
| 2024 | 403 | 97 | 0% (0) | 10% | $275,931 |
| 2023 | 284 | 64 | 0% (0) | 14% | $199,989 |
| 2022 | 322 | 72 | None | 5% | $105,671 |
| 2021 | 378 | 73 | 0% (0) | None | $27,245 |
| 2020 | 434 | 82 | 0% (0) | None | $291,457 |
| 2019 | 411 | 80 | 0% (0) | 8% | $186,509 |
| 2018 | 378 | 72 | None | None | $146,332 |
| 2017 | 366 | 63 | 0% (0) | None | $162,252 |
| 2016 | 411 | 72 | 0% (0) | 11% | $112,685 |
| 2015 | 211 | 59 | None | 18% | $85,687 |
| 2014 | 146 | 45 | 0% (0) | 17% | $9,340 |
| 2013 | 221 | 61 | 0% (0) | 13% | $16,025 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Gammagard Liquid | Immune globulin | 22 | $75,773 | $3,444 |
| Droxidopa | None | 16 | $5,847 | $365 |
| Pyridostigmine | None | 35 | $2,487 | $71 |
| Midodrine | None | 28 | $1,398 | $50 |
| Fludrocortisone Acetate | None | 15 | $671 | $45 |
| Baclofen | None | 11 | $293 | $27 |
| Gabapentin | None | 13 | $96 | $7 |
2022: 10 drugs
| Droxidopa | 23 | $19,564 | $851 |
| Midodrine | 36 | $2,677 | $74 |
| Pyridostigmine | 41 | $2,490 | $61 |
| Baclofen | 21 | $823 | $39 |
| Memantine | 14 | $806 | $58 |
| Duloxetine | 24 | $366 | $15 |
| Fludrocortisone Acetate | 13 | $366 | $28 |
| Gabapentin | 14 | $146 | $10 |
| Methotrexate | 12 | $118 | $10 |
| Carbidopa-Levodopa | 12 | $87 | $7 |
2021: 10 drugs
| Midodrine | 40 | $4,045 | $101 |
| Pyridostigmine | 61 | $2,782 | $46 |
| Fludrocortisone Acetate | 28 | $1,352 | $48 |
| Mycophenolate Mofetil | 12 | $474 | $39 |
| Gabapentin | 30 | $460 | $15 |
| Baclofen | 22 | $367 | $17 |
| Duloxetine | 24 | $323 | $13 |
| Memantine | 11 | $317 | $29 |
| Prednisone | 15 | $165 | $11 |
| Clonidine | 14 | $89 | $6 |
2020: 9 drugs
| Midodrine | 52 | $3,606 | $69 |
| Pyridostigmine | 54 | $2,549 | $47 |
| Fludrocortisone Acetate | 58 | $1,995 | $34 |
| Mycophenolate Mofetil | 11 | $552 | $50 |
| Duloxetine | 20 | $314 | $16 |
| Baclofen | 21 | $252 | $12 |
| Gabapentin | 28 | $222 | $8 |
| Prednisone | 14 | $108 | $8 |
| Escitalopram | 12 | $74 | $6 |
2019: 10 drugs
| Northera | 12 | $167,933 | $13,994 |
| Pyridostigmine | 80 | $3,345 | $42 |
| Midodrine | 47 | $3,128 | $67 |
| Fludrocortisone Acetate | 45 | $1,579 | $35 |
| Desmopressin Acetate | 13 | $702 | $54 |
| Galantamine Hbr | 11 | $595 | $54 |
| Potassium Chloride | 12 | $427 | $36 |
| Levetiracetam | 13 | $406 | $31 |
| Gabapentin | 22 | $356 | $16 |
| Metoprolol | 15 | $60 | $4 |
2018: 12 drugs
| Pyridostigmine | 49 | $2,178 | $44 |
| Midodrine | 70 | $2,155 | $31 |
| Fludrocortisone Acetate | 46 | $1,236 | $27 |
| Desmopressin Acetate | 15 | $907 | $60 |
| Levetiracetam | 11 | $544 | $49 |
| Cyproheptadine | 13 | $468 | $36 |
| Potassium Chloride | 19 | $287 | $15 |
| Carbidopa-Levodopa | 11 | $225 | $20 |
| Gabapentin | 16 | $211 | $13 |
| Clonazepam | 24 | $118 | $5 |
| Atenolol | 13 | $89 | $7 |
| Metoprolol | 13 | $49 | $4 |
2017: 9 drugs
| Northera | 25 | $150,937 | $6,037 |
| Midodrine | 81 | $2,339 | $29 |
| Fludrocortisone Acetate | 43 | $986 | $23 |
| Pyridostigmine | 26 | $982 | $38 |
| Potassium Chloride | 22 | $333 | $15 |
| Desmopressin Acetate | 12 | $215 | $18 |
| Gabapentin | 21 | $215 | $10 |
| Atenolol | 20 | $82 | $4 |
| Buspirone | 12 | $37 | $3 |
2016: 13 drugs
| Northera | 16 | $86,036 | $5,377 |
| Midodrine | 56 | $3,567 | $64 |
| Pyridostigmine | 32 | $1,219 | $38 |
| Levetiracetam | 21 | $954 | $45 |
| Azathioprine | 12 | $571 | $48 |
| Oxcarbazepine | 18 | $560 | $31 |
| Baclofen | 32 | $528 | $17 |
| Fludrocortisone Acetate | 27 | $421 | $16 |
| Propranolol | 12 | $416 | $35 |
| Gabapentin | 22 | $378 | $17 |
| Carbidopa-Levodopa | 11 | $267 | $24 |
| Potassium Chloride | 12 | $210 | $18 |
| Clonazepam | 13 | $118 | $9 |
2015: 7 drugs
| Northera | 16 | $72,540 | $4,534 |
| Lyrica | 14 | $5,985 | $427 |
| Pyridostigmine | 17 | $755 | $44 |
| Midodrine | 16 | $663 | $41 |
| Carbidopa-Levodopa | 16 | $312 | $20 |
| Gabapentin | 19 | $287 | $15 |
| Levetiracetam | 16 | $141 | $9 |
2014: 2 drugs
| Midodrine | 25 | $946 | $38 |
| Carbidopa-Levodopa | 14 | $589 | $42 |
2013: 4 drugs
| Carbidopa-Levodopa | 31 | $1,483 | $48 |
| Midodrine | 18 | $819 | $45 |
| Gabapentin | 18 | $352 | $20 |
| Donepezil | 20 | $257 | $13 |
Money from drug and device companies
$1,644 in 2025
| 2025 | 2 | 3 | $1,611 | $1,644 |
| 2024 | 1 | 1 | None | $138 |
| 2023 | 2 | 4 | $2,148 | $2,348 |
| 2022 | 1 | 2 | None | $145 |
| 2021 | 2 | 5 | $13,815 | $13,815 |
| 2020 | 2 | 3 | $2,475 | $2,593 |
| 2019 | 2 | 20 | $11,200 | $13,350 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Wainua | $1,611 | 1 payment
|
| Ucb | Zilbrysq | $33 | 2 payments
|
See all 3 published payments
| Ucb | Education · 2025-12-12 | Zilbrysq | $18 |
| Ucb | Education · 2025-05-30 | Rystiggo | $15 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-03-12 | Wainua | $1,611 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $138
| Alnylam Pharmaceuticals | None | $138 | 1 payment
|
2023: $2,348
| AstraZeneca Pharmaceuticals LP | None | $2,302 | 3 payments
|
| Alexion Pharmaceuticals | None | $46 | 1 payment
|
2022: $145
| Alnylam Pharmaceuticals | Onpattro | $145 | 2 payments
|
2021: $13,815
| Alnylam Pharmaceuticals | Onpattro | $9,675 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $4,140 | 1 payment
|
2020: $2,593
| Akcea Therapeutics | Tegsedi | $2,475 | 2 payments
|
| Alnylam Pharmaceuticals | None | $118 | 1 payment
|
2019: $13,350
| Akcea Therapeutics | Tegsedi | $8,506 | 8 payments
|
| Alnylam Pharmaceuticals | Onpattro | $4,844 | 12 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Alnylam Pharmaceuticals Inc. · Expanded Access Protocol of Patisiran for Patients With Hereditary Attr Amyloidosis Hattr · 2019 | Their institution | $159,876 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1730130576
- Licence
- CA C54540, WI NEUROLOGYCalifornia C54540: Current · expires 2027-02-28
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- WI 31615000
- Taxonomy
- Federal specialty code 2084N0600X (2084N0600X); Federal specialty code 204R00000X (204R00000X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-05-15
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304